| http://purl.uniprot.org/citations/18754880 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/18754880 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/18754880 | http://www.w3.org/2000/01/rdf-schema#comment | "We recently cloned a variant form of erythropoietin-producing hepatocyte (Eph)B6, a member of the Eph receptor tyrosine kinase family. In the present study, we examined the expression of the EphB6 variant (EphB6v) in a panel of brain tumor cell lines and glioblastoma tissues and we found that EphB6v was preferentially expressed in malignant brain tumors, such as glioblastomas and anaplastic astrocytomas. The EphB6v has a unique 54 amino acid sequence at the C-terminal that is not found in normal EphB6. Therefore, we attempted to identify antigenic peptides unique to EphB6v for immunotherapy. The two EphB6v-derived peptides exhibited the ability to bind to human leukocyte antigen (HLA)-A0201 molecules, and each of them was able to induce cytotoxic T lymphocytes in vitro in the peripheral blood mononuclear cells of HLA-A2(+) glioma patients. The cytotoxicity was mediated by peptide-specific CD8(+) T cells in an HLA-A2-restricted manner. The expression of EphB6v was also observed in different types of cancer (e.g. lung, colon, stomach, liver and pancreatic) cells. Taken together, the two peptides derived from EphB6v might be appropriate targets for peptide-based specific immunotherapy for HLA-A2(+) patients with various cancers."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.org/dc/terms/identifier | "doi:10.1111/j.1349-7006.2008.00866.x"xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.org/dc/terms/identifier | "doi:10.1111/j.1349-7006.2008.00866.x"xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Itoh K."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Itoh K."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Jin M."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Jin M."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Yamada A."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Yamada A."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Shichijo S."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Shichijo S."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Nikawa J."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Nikawa J."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Komohara Y."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Komohara Y."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Yamanaka R."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/author | "Yamanaka R."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/date | "2008"xsd:gYear |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/date | "2008"xsd:gYear |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/name | "Cancer Sci."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/name | "Cancer Sci."xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/pages | "1656-1662"xsd:string |
| http://purl.uniprot.org/citations/18754880 | http://purl.uniprot.org/core/pages | "1656-1662"xsd:string |